Are GLP-1 drugs actually causing 'Ozempic babies'?

What did @insideedition actually say?

The video profiles two women who conceived after starting semaglutide (Ozempic) for weight loss, framing them as part of a new "Ozempic baby" phenomenon. The central claim is that GLP-1 drugs may be boosting fertility, either through weight-related hormone changes or by reducing the effectiveness of oral contraceptives. One expert quoted in the video explains it plainly: "if you have excess fat, you can make excess hormones and then that can cause a hormone imbalance." The segment also issues two safety warnings: stop the drug immediately if pregnant, and be aware that these medications may interfere with birth control pills. To Inside Edition's credit, they did not claim Ozempic is a fertility treatment. They framed this as anecdotal and called in medical voices to temper the enthusiasm. That's more responsible than most TikTok health content. But the mechanism they leaned on is only part of the picture, and the birth control claim deserves more scrutiny than it got.

Does the science back this up?

Partially, yes. The weight-loss-to-hormone-balance pathway is real and reasonably well supported. Obesity is associated with elevated estrogen, elevated insulin, and suppressed sex hormone-binding globulin, all of which can impair ovulation. Losing even 5-10% of body weight can restore ovulatory cycles in women with obesity-related anovulation (Kiddy et al., 1992, BMJ). So the idea that GLP-1-driven weight loss could improve fertility is biologically plausible.

There is also emerging data suggesting GLP-1 receptors may be expressed in ovarian tissue, which could mean a more direct effect beyond weight loss alone. A 2024 observational study published in Annals of Internal Medicine (Weiss et al.) found higher rates of unintended pregnancy among women on GLP-1 agonists compared to matched controls on other weight-loss interventions, though the absolute numbers were small and the study could not confirm causation.

The birth control interaction claim has a plausible mechanism too. Semaglutide slows gastric emptying, which could theoretically reduce peak absorption of oral contraceptives. Novo Nordisk's own prescribing information for Wegovy flags this as a concern, particularly for pills taken with food. However, a pharmacokinetic substudy found only modest effects on levonorgestrel absorption, not enough to declare oral contraceptives unreliable across the board.

What did they get wrong (or right)?

They got the general direction right but oversimplified in a way that could cause real harm. The video implies a clean cause-and-effect relationship when the evidence is still largely anecdotal and mechanistic. There are no randomized controlled trials demonstrating that GLP-1 drugs improve fertility as a primary outcome. Every "Ozempic baby" story could reflect weight loss from any intervention, spontaneous fertility recovery, or simple chance in a population that was already trying to conceive.

The birth control warning was accurate but underdeveloped. Saying the drugs "can sometimes make birth control pills less effective" without explaining what that means practically, or what women should do about it, is incomplete. Guidelines from the manufacturer and some reproductive endocrinologists suggest using barrier methods as a backup, especially in the first few weeks of GLP-1 therapy. That context was absent.

What they got right: the safety call to stop GLP-1 drugs immediately upon confirmed pregnancy is consistent with current clinical guidance. Semaglutide is rated FDA Pregnancy Category X equivalent under current labeling. Stopping promptly was the correct and responsible message.

What should you actually know?

If you have obesity-related infertility, particularly tied to PCOS or anovulation, weight loss through any means, including GLP-1 therapy, may genuinely improve your chances of conception. That is a real and evidence-supported connection. What it is not: a proven fertility treatment, a green light to take Ozempic specifically to get pregnant, or a substitute for an evaluation by a reproductive endocrinologist.

If you are sexually active and on a GLP-1 drug and do not want to become pregnant, talk to your prescriber about contraception. The oral contraceptive interaction is real enough to take seriously, even if the magnitude is debated. A backup method is a reasonable precaution.

If you are already pregnant: stop the GLP-1 drug and contact your OB. Current animal data and the precautionary principle both point toward avoiding semaglutide and tirzepatide during pregnancy. There are no long-term human safety data for fetal exposure to these drugs.

• GLP-1 drugs are not FDA-approved for fertility treatment.
• The "Ozempic baby" framing conflates weight-loss benefits with a specific drug effect that has not been isolated in controlled trials.
• Anyone using these drugs should be using reliable contraception unless they are actively trying to conceive and have discussed this with a physician.